Market Access

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

In order to provide both profitability and medication access, a balancing act is required.

Duplicate rebates have resulted in revenue leakage for manufacturers.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's drug plus model.

Experts explore ways in which the financial sector refined the healthcare landscape, including its evolutions throughout the years.

All healthcare stakeholders must participate to dismantle barriers and ensure access to medicines that save lives.

Analysis examines how social and healthcare factors play a role.

Soaring healthcare costs show little sign of abating in 2024, and concerns about the affordability of medications and medical services continue to grow, despite investments in technology, clinical innovation, and efforts to manage utilization and waste.

Morgan Company report makes the case for expanding coverage for GLP-1s beyond diabetes treatment and into the weight loss class, but are employers on board?

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Over the past year, Pharma Commerce’s digital coverage featured a variety of subject matters, ranging from how to calculate 340B prices, to the future of pharmacy.

The most popular pieces pertaining to the supply chain featured ADMs, vaccine supply chains, and wholesalers.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

Will result from Medicare reforms, despite increased drug uptake.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration.

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Director of Berkeley Research Group explains changes to 340B moving forward.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

Berkeley Research Group Director discusses what to expect at his upcoming session.

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.